The first-in-class pro-apoptotic peptide PEP-010 is effective in monotherapy and in combination with paclitaxel on resistant ovarian adenocarcinoma cell models.

MLA

Lacroix, Aline, et al. “The First-in-Class pro-Apoptotic Peptide PEP-010 Is Effective in Monotherapy and in Combination with Paclitaxel on Resistant Ovarian Adenocarcinoma Cell Models.” Frontiers in Pharmacology, Aug. 2024, pp. 1–7. EBSCOhost, https://doi.org/10.3389/fphar.2024.1444973.

APA

Lacroix, A., Farhat, R., Robert, A., Brenner, C., Wiels, J., & Germini, D. (2024). The first-in-class pro-apoptotic peptide PEP-010 is effective in monotherapy and in combination with paclitaxel on resistant ovarian adenocarcinoma cell models. Frontiers in Pharmacology, 1–7. https://doi.org/10.3389/fphar.2024.1444973

Chicago

Lacroix, Aline, Rayan Farhat, Aude Robert, Catherine Brenner, Joëlle Wiels, and Diego Germini. 2024. “The First-in-Class pro-Apoptotic Peptide PEP-010 Is Effective in Monotherapy and in Combination with Paclitaxel on Resistant Ovarian Adenocarcinoma Cell Models.” Frontiers in Pharmacology, August, 1–7. doi:10.3389/fphar.2024.1444973.